缬沙坦与原发性高血压患者高敏C 反应蛋白和尿微量白蛋白 的相关性分析

目的:探讨缬沙坦与原发性高血压患者高敏C反应蛋白和尿微量白蛋白的相关性。方法:随机对我院收治的132例原发性高血压患者分为实验组以及对照组,对照组采用常规治疗,实验组在对照组基础上联合使用缬沙坦,同期选择30名健康人群作为健康组,对三组研究对象进行血压、心率以及高敏C反应蛋白和尿微量白蛋白的测定。结果:实验组与对照组在治疗前后组内比较有明显差异性(P<0.05),但组间比较无明显差异性(P>0.05);实验组患者在治疗后其高敏C反应蛋白和尿微量白蛋白含量明显低于对照组(P>0.05),但高于健康组(P>0.05)。结论:对原发性高血压患者在常规治疗中联合使用缬沙坦,可降低其高敏C反应蛋白和尿微量白蛋白,减缓患者血管内皮的损伤,提高患者治疗效果。

Analysis on Correlation of Valsartan with Levels of High-sensitivity C-reactive Protein andUrinaryAlbumin ofPatientswith EssentialHypertension

Objective: To investigate the correlation of valsartan with the high-sensitivity C-reactive protein and urinary albumin levels of patients with essential hypertension.Methods: 132 patients with essential hypertension in our hospital were randomly divided into experimental group and control group.Control group were treated with conventional treatment,and the experimental group were treated with the combined use of valsartan and conventional treatment.At the same time,30 healthy people were chosen as the healthy group.Subjects of three groups as blood pressure,heart rate and levels of high sensitivity C-reactive protein and urinary albumin were determined.Results: Compared with detection results of before treatment,there were significant differences in results of after treatment in both experimental group and control group(P <0.05),but there was no significant difference between the groups(P> 0.05).The high-sensitivity C-reactive protein and urinary albumin levels were significantly lower in experimental group than the control group after treatment(P>0.05),but higher than the healthy group(P>0.05).Conclusion: The conventional treatment plus valsartan can reduce the high-sensitivity C-reactive protein and urinary albumin levels of patients with essential hypertension,reduce vascular endothelial injury,and improve therapy outcomes.